

CITATION REPORT

List of articles citing

Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.

DOI: 10.1080/13651501.2022.2030757

International Journal of Psychiatry in Clinical Practice, 2022, , 1-11.

Source: <https://exaly.com/paper-pdf/134437913/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Intermittent theta burst stimulation (iTBS) versus 10-Hz high-frequency repetitive transcranial magnetic stimulation (rTMS) to alleviate treatment-resistant unipolar depression: A randomized controlled trial (THETA-DEP). <i>Brain Stimulation</i> , 2022 ,	5.1	1
3	Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study. <i>Frontiers in Psychiatry</i> , 13,	5	1
2	Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study. 13,		0
1	Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy. 2023 , 41, 209-225		0